China’s NHC Issues Guidelines to Improve Pediatric Medication Management
The National Health Commission (NHC) has released a notification aimed at refining management measures for...
Fineline Cube
China’s Multi-Bureau Plan Aims to Eradicate Cervical Cancer by 2030
The National Health Commission (NHC), Ministry of Education, Ministry of Civil Affairs, and six other...
JS InnoPharm’s US Subsidiary Initiates Phase I Trial for AURKA Inhibitor VIC-1911
Shanghai-based JS InnoPharm Ltd has announced the initiation of a Phase I clinical study by...
Akeso Receives First $300M Installment from Summit for Bispecific Antibody Ivonescimab
Akeso Inc. (HKG: 9926) has announced receiving the first installment of USD 300 million as...
NMPA Proposes Emergency Use Management Measures for Medical Devices
The National Medical Products Administration (NMPA) has released the “Medical Device Emergency Use Management Measures”...
InnoCare’s Gunagratinib Shows Promising Data in Cholangiocarcinoma at ASCO-GI 2023
Beijing InnoCare Pharma Tech Co. (HKG: 9969), a China-based biotech specializing in cancer and autoimmune...
Exegenesis Bio Gains FDA Approval for Gene Therapy EXG102-031 in Wet AMD
Hangzhou-based clinical stage gene therapy firm Exegenesis Bio has announced receiving approval from the US...
Simcere’s Cosela Receives First Prescription in China for CDK4/6 Inhibition
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the issuance of the first prescription for...
China Updates Export Controls on Technologies, Adds Gene Editing to List
The Ministry of Finance (MOF) has released an updated notification regarding technologies banned and restricted...
Novartis’ Kisqali Receives NMPA Approval for Premenopausal Breast Cancer
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval from the National Medical...
Fosun Pharma’s Comirnaty Bivalent Vaccine Approved in Macau for Booster Shots
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its Comirnaty...
HuidaGene Receives FDA IND Approval for Ophthalmology Gene Therapy HG004
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...
HutchMed Signs Licensing Deal with Takeda for Global Fruquintinib Development
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced a licensing deal with Japanese...
Tianjin-Based Protein T Raises RMB 100 Million in Series A Financing
Tianjin-based biotech Protein T, focused on multi-omics research, has reportedly raised close to RMB 100...
Ascletis Receives IND Approval for ASC10 in Monkeypox Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving Investigational New Drug (IND) approval from...
Legend Biotech’s Carvykti Meets Primary Endpoint in CARTITUDE-4 Phase III Study
Legend Biotech (NASDAQ: LEGN) has released positive data from the CARTITUDE-4 Phase III study, evaluating...
CSPC’s Octreotide Long-Acting Injection Approved for Acromegaly Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
BeiGene’s Brukinsa Approved by FDA for Chronic Lymphocytic Leukemia
China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the US FDA has...
Dartsbio Pharmaceuticals Secures RMB 100 Million in Series B Financing
Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has reportedly raised over RMB 100 million in a...